Monoclonal Antibodies Market in Colorectal Cancer to 2019 | Industry Shares, Size, Trend, Analysis, and Forecasts Report Available Online by Researchmoz.us
Albany, New York (PRWEB) December 13, 2013
GBI Research, has released the pharma report - “Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a number of oncology indications. While compelling late-stage candidates are absent from the current pipeline, the anticipated rise in total prevalence of colorectal cancer in the top eight markets may inspire further investment.
Full Report With TOC at http://www.researchmoz.us/monoclonal-antibodies-market-in-colorectal-cancer-to-2019-favorable-pricing-policy-in-the-us-and-rising-prevalence-in-europe-and-japan-ensures-market-growth-report.html.
Pricing patterns for mAbs are highly favorable in the US, the largest market for colorectal cancer, and patent expirations are not expected to have a substantial effect on any of the featured markets. As a result of this, GBI Research believes the global market has the potential to grow to a value of $5.5 billion by 2019.
A brief introduction to colorectal cancer, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms.
In-depth analysis of the three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy.
A comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets.
Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type, in addition to an in-depth analysis of clinical trial primary endpoints.
Browse All Latest Market Research Report at http://www.researchmoz.us/latest-report.html.
Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets.
Discussion of the drivers and barriers for market growth.
In-depth analysis of all licensing and co-development deals that have occurred in the colorectal cancer market since 2006.
Reasons to Buy
Understand the role of mAbs in the treatment of colorectal cancer and their relation to chemotherapies and targeted small molecule therapies.
Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
All GBI Market Research Report at http://www.researchmoz.us/publisher/gbi-research-2.html.
Observe the trends in clinical trial duration and size amongst clinical phases and molecule types. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for colorectal cancer therapeutics.
Observe the shift in clinical trial endpoints throughout clinical phases of development, and use this data to potentially influence any future developmental programs.
Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the colorectal cancer mAbs market.
Global and China Insulin Industry Report, 2013 - 2017
As the third largest human (http://www.researchmoz.us/global-and-china-insulin-industry-report-2013-2017-report.html) health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%. And insulin as the important diabetes medication has also seen increasing market size. In 2012 the global insulin market size reached US$20.8 billion, a year-on-year rise of 12.9%, basically monopolized by Novo Nordisk, Sanofi and Eli Lilly, which altogether accounted for 88.7% of market share.
Equine Healthcare Market
The global equestrian market (http://www.researchmoz.us/equine-healthcare-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019-report.html) is a multi-billion dollar industry that comprises horse racing and betting, leisure and competitive riding and has spawned and supports multifarious secondary markets; the equine healthcare market ranks as the one of the key secondary markets. This report exclusively studies the market for equine healthcare from varied aspects such as, in terms of equine diagnostic products, equine therapeutic products and equine supplement products; and is thus classified into three prime segments namelyequine diagnostic products market, equine therapeutic products market and equine supplement products market.
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948